Media
Press releases
Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per…
Quotient Limited Provides Positive Updates on MosaiQ’s Initial Serological Disease Screening and Expanded Immunohematology Microarrays, on Hypercare Launch and on a Successful Facility Audit and Reports Second Quarter Fiscal 2020 Financial Results
JERSEY, Channel Islands, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, provided updates on several important developments in connection with the transformational MosaiQ multiplexing platform. These included…
Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial
JERSEY, Channel Islands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray.
Quotient Limited to Report Second Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2019, will be released before market open on Monday, November 4, 2019.
Quotient Announces Positive Verification and Validation Results for Extended Immunohematology Microarray and Updates on Hypercare Sites and Revenue Performance in the Quarter
JERSEY, Channel Islands, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the positive Verification & Validation (V&V) data for the Extended Immunohematology (IH) Microarray.
Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results
JERSEY, Channel Islands, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today provided an update on the commencement of its EU hypercare launch during July 2019; on the completion of its initial Serological…
Quotient Limited to Report First Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands, July 22, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2019, will be released before market open on Monday, August 5, 2019.
Quotient Limited to Report First Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands, July 22, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2019, will be released before market open on Monday, August 5, 2019.
Quotient Board Announces Contract Extension of CEO Franz Walt
JERSEY, Channel Islands, July 02, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Board of Directors’ decision to amend Chief Executive Officer (CEO) Franz Walt’s employment…
Quotient Limited Announces the Submission of the Initial SDS Microarray CE mark Filing for MosaiQ™
JERSEY, Channel Islands, July 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the submission of its completed dossier for the CE Mark (Conformité Européenne) of its initial…